Company / SG&A Expense
Doximity SG&A Expense History
FY2019-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$45.7M
FY2024
5-year range
$35.7M / $45.7M
FY2020-FY2024
Trend
+20.7%
vs FY2023
Sector context
#140 of 152
Health Care
What the data says
Among 152 Health Care companies, Doximity is in the top 8% for sg&a expense. SG&A Expense has increased for 5 consecutive years, from $7M in FY2019 to $46M in FY2024.
Based on SEC 10-K filings.
$46M in FY2024 with a 5-year CAGR of +43.7%.
Increased from $37M to $46M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +8.5%
- 5-Year CAGR
- +43.7%
- 10-Year CAGR
- -
Sector benchmark
Top 8% in Health CareTop 8% of 152This company $45.7M Sector average $182.7B
▼
-100.0% below sector average
Key checks
Key Insights
- Doximity's sg&a expense has grown for 5 consecutive years.
- 5-year CAGR of +43.7%, indicating consistent growth.
- In FY2024, sg&a expense increased 20.7% year-over-year.
- Ranks #140 out of 152 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.16 (safe zone, above 2.9 threshold)
- Strong profit margin: 39.1%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $45.7M | +20.7% |
| FY2023 | $37.8M | +2.9% |
| FY2022 | $36.7M | +2.8% |
| FY2021 | $35.7M | +116.7% |
| FY2020 | $16.5M | +121.6% |
| FY2019 | $7.4M | - |
As of FY2024 · SEC 10-K · Updated Mar 29, 2026